BURLINGTON, Vt (AP) – More than 280 volunteers have been enrolled in a phase 3 trial of another vaccine against the virus that causes COVID-19, the University of Vermont Medical Center said Friday.
UVM has enrolled the volunteers to help study the AstraZeneca COVID-19 vaccine. Some of the volunteers will receive the vaccine while others will receive a placebo.
Nearly two-thirds of those enrolled are over age 65. Additionally, more than 12% of participants identify as black, indigenous or persons of color.
The AstraZeneca vaccine has not been approved for use in the United States, but it has been approved for use in the United Kingdom and Brazil.
Data from the trial UVM is participating in is hoped to be ready for review by the Food and Drug Administration in the coming weeks or months.
Participants in the study UVM is participating in will be monitored for about two years.
Vermont health officials are currently working to inoculate Vermonters against COVID-19 with vaccines from Pfizer and Moderna that have approved for use in the United States.
Copyright © 2021 The Washington Times, LLC.